Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse - PubMed (original) (raw)
Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse
L O González et al. Br J Cancer. 2007.
Abstract
An immunohistochemical study was performed using tissue microarrays and specific antibodies against matrix metalloproteinase (MMP)-1, -2, -7, -9, -11, -13 and -14, tissular inhibitors of metalloproteinase (TIMP)-1, -2 and -3. More than 2600 determinations on cancer specimens from 131 patients with primary ductal invasive tumours of the breast were performed. To identify specific groups of tumours with distinct expression profiles the data were analysed by unsupervised hierarchical cluster analysis by each cellular type. We did not find well-defined cluster of cases for tumour cells or fibroblastic cells. However, for mononuclear inflammatory cells the dendogram shows a first-order division of the tumours into two distinct MMP/TIMP molecular profiles, designated group 1 (n=89) and group 2 (n=42). Matrix metalloproteinase-7, -9, -11, -13 and -14, and TIMP-1 and -2, were identified as showing significant high expression in group 2 compared with group 1. Multivariate analysis demonstrated that clustering for mononuclear inflammatory cells was the most potent independent factor associated with distant relapse-free survival (group 2: 5.6 (3.5-9.6), P<0.001). We identify a phenotype of mononuclear inflammatory cells infiltrating tumours, which is associated with the development of distant metastasis. Therefore, this finding suggests that these host inflammatory cells could be a possible target for inhibition of metastasis.
Figures
Figure 1
Left: examples of tissue with immunostaining for the more significant proteins in patients with tumours belong to poor prognostic group (cluster 2 group: A, B and C) and better prognostic group (cluster 1 group: D, E and F; magnification × 400). (A) Immunohistochemical staining of matrix metalloproteinase (MMP)-11 in inflammatory mononuclear cells, tumour cells and fibroblastic cells. (B) Immunohistochemical staining of MMP-9 in inflammatory mononuclear cells, tumour cells and fibroblastic cell negatives. (C) Immunohistochemical staining of tissular inhibitors of metalloproteinase (TIMP)-1 in inflammatory mononuclear cells and in fibroblastic cells, tumour cell negatives. (D) No immunohistochemical staining of MMP-9 in inflammatory mononuclear cells, tumour cells and fibroblastic cells. (E) Immunohistochemical staining of MMP-11 in tumour cells, inflammatory mononuclear cells and fibroblastic cell negatives. (F) Immunohistochemical staining of TIMP-1 in fibroblastic cells, inflammatory mononuclear cells and tumour cell negatives. In all cases, inflammatory mononuclear cells are indicated with small arrows, and fibroblastic cells with large arrows.
Figure 2
Hierarchical clustering analysis of global matrix metalloproteinases (MMPs)/tissular inhibitors of metalloproteinases (TIMPs) expressions in the different cell types of breast cancer as measured by immunohistochemistry on tissue microarray (TMA). Graphical representation of hierarchical clustering results in tumour cells (A), fibroblasts (B) and mononuclear inflammatory cells (C). Rows, tumoural samples; columns, MMPs/TIMPs. Protein expressions are depicted according to a color scale: red, positive staining; green, negative staining; grey, missing data. No major clusters of tumours are shown in tumour cells and fibroblasts. Two major clusters of tumours (1 and 2) are shown in mononuclear inflammatory cells.
Figure 3
(A) Representative Western blots of immunoreactive matrix metalloproteinases (MMPs). (A) Eighty micrograms of cytosol extract from seven human breast carcinomas (lanes 2–8) were subject to 12% SDS–PAGE and transferred onto a nitrocellulose membrane and then immunolabelled with MMP-1, -11, -13, -14 and _β_-actin (used as loading control) antiserum. Lane 1, molecular weight marker (50 kDa). (B) Western blots of immunoreactive MMP-11 and _β_-actin (used as loading control) from two human breast carcinomas (lanes 1 and 2) and from human placenta (used as positive control, lane 3).
Figure 4
Kaplan–Meier survival curves as a function of the two major clusters of tumours (Groups 1 and 2) shown in mononuclear inflammatory cells.
Similar articles
- Study of matrix metalloproteinases and their inhibitors in breast cancer.
Vizoso FJ, González LO, Corte MD, Rodríguez JC, Vázquez J, Lamelas ML, Junquera S, Merino AM, García-Muñiz JL. Vizoso FJ, et al. Br J Cancer. 2007 Mar 26;96(6):903-11. doi: 10.1038/sj.bjc.6603666. Epub 2007 Mar 6. Br J Cancer. 2007. PMID: 17342087 Free PMC article. - Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis.
Fernandez-Garcia B, Eiró N, Marín L, González-Reyes S, González LO, Lamelas ML, Vizoso FJ. Fernandez-Garcia B, et al. Histopathology. 2014 Mar;64(4):512-22. doi: 10.1111/his.12300. Epub 2013 Nov 28. Histopathology. 2014. PMID: 24117661 - Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast.
Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Viña A, Rodriguez JC, Lamelas ML, Vizoso F. Gonzalez LO, et al. Histopathology. 2008 Oct;53(4):403-15. doi: 10.1111/j.1365-2559.2008.03136.x. Histopathology. 2008. PMID: 18983606 - Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO, Corte MD, Junquera S, González-Fernández R, del Casar JM, García C, Andicoechea A, Vázquez J, Pérez-Fernández R, Vizoso FJ. González LO, et al. Hum Pathol. 2009 Sep;40(9):1224-33. doi: 10.1016/j.humpath.2008.12.022. Epub 2009 May 12. Hum Pathol. 2009. PMID: 19439346 - Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Curran S, et al. Clin Cancer Res. 2004 Dec 15;10(24):8229-34. doi: 10.1158/1078-0432.CCR-04-0424. Clin Cancer Res. 2004. PMID: 15623598
Cited by
- Acute-phase serum amyloid A for early detection of hepatocellular carcinoma in cirrhotic patients with low AFP level.
Wu JL, Su TH, Chen PJ, Chen YR. Wu JL, et al. Sci Rep. 2022 Apr 6;12(1):5799. doi: 10.1038/s41598-022-09713-9. Sci Rep. 2022. PMID: 35388082 Free PMC article. - Relationship between Metalloprotease-7 and -14 and Tissue Inhibitor of Metalloprotease 1 Expression by Mucosal Stromal Cells and Colorectal Cancer Development in Inflammatory Bowel Disease.
Altadill A, Eiro N, González LO, Andicoechea A, Fernández-Francos S, Rodrigo L, García-Muñiz JL, Vizoso FJ. Altadill A, et al. Biomedicines. 2021 Apr 30;9(5):495. doi: 10.3390/biomedicines9050495. Biomedicines. 2021. PMID: 33946534 Free PMC article. - Joint Tumor Bud-MMP/TIMP Count at the Invasive Front Improves the Prognostic Evaluation of Invasive Breast Carcinoma.
González LO, Eiro N, Fraile M, Sánchez R, Andicoechea A, Fernández-Francos S, Schneider J, Vizoso FJ. González LO, et al. Biomedicines. 2021 Feb 16;9(2):196. doi: 10.3390/biomedicines9020196. Biomedicines. 2021. PMID: 33669393 Free PMC article. - MMP1 and MMP11 Expression in Peripheral Blood Mononuclear Cells upon Their Interaction with Breast Cancer Cells and Fibroblasts.
Eiro N, Cid S, Aguado N, Fraile M, de Pablo N, Fernández B, Domínguez F, González LO, Vizoso FJ. Eiro N, et al. Int J Mol Sci. 2020 Dec 31;22(1):371. doi: 10.3390/ijms22010371. Int J Mol Sci. 2020. PMID: 33396463 Free PMC article. - Prognostic role of matrix metalloproteinase 9 in early breast cancer.
Kalavska K, Cierna Z, Karaba M, Minarik G, Benca J, Sedlackova T, Kolekova D, Mrvova I, Pindak D, Mardiak J, Mego M. Kalavska K, et al. Oncol Lett. 2021 Feb;21(2):78. doi: 10.3892/ol.2020.12339. Epub 2020 Nov 30. Oncol Lett. 2021. PMID: 33363615 Free PMC article.
References
- Adams TE, Alpert S, Hanahan D (1987) Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature 325: 223–228 - PubMed
- Anderson IC, Sugarbaker DJ, Ganju RK, Tsarwhas DG, Richards WG, Sunday M, Kobzik L, Shipp MA (1995) Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res 55: 4120–4126 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous